FDA Grants Priority Review to Pharming’s Lower-Dose Joenja for…

Event summary

FDA accepted Pharming’s sNDA for lower doses of Joenja (leniolisib) to treat children aged 4+ with APDS weighing 13–27 kg.
Priority Review designation sets PDUFA target action date of January 30, 2027.
Application supported by Phase III study data showing improvements in lymphadenopathy and naive B cells.
Follows September 2026 approval of Joenja for children aged 4–11 weighing ≥27 kg.

The big picture

Pharming’s sNDA acceptance for lower-dose Joenja underscores its strategic focus on expanding treatment options for rare immune diseases, particularly in underserved pediatric populations. The Priority Review designation highlights the unmet medical need for APDS, a progressive condition with significant diagnostic delays. This move positions Pharming to solidify its leadership in targeted therapies for primary immunodeficiencies, while regulatory success could drive further commercial and clinical momentum.

What we're watching

Regulatory Timing: Whether the FDA meets the January 2027 PDUFA date for approval, accelerating access for younger APDS patients.
Market Expansion: How Pharming leverages this approval to expand Joenja’s reach in the rare disease space, particularly in pediatric indications.
Competitive Dynamics: The pace at which competitors develop alternative treatments for APDS, potentially challenging Pharming’s market position.